Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)

Frank Kroschinsky; Jan Moritz Middeke; Martin Janz; Georg Lenz; Mathias Witzens-Harig; Reda Bouabdallah; Paul La Rosée; Andreas Viardot; Gilles Salles; Seok Jin Kim; Tae Min Kim; Oliver Ottmann; Joerg Chromik; Anne Marie Quinson; Ute von Wangenheim; Ute Burkard; Andreas Berk; Norbert Schmitz

doi:10.1007/s10637-020-00949-8

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)

Frank Kroschinsky
, Jan Moritz Middeke
, Martin Janz
, Georg Lenz
, Mathias Witzens-Harig
, Reda Bouabdallah
, Paul La Rosée
, Andreas Viardot
, Gilles Salles
, Seok Jin Kim
, Tae Min Kim
, Oliver Ottmann
, Joerg Chromik
, Anne Marie Quinson
, Ute von Wangenheim
, Ute Burkard
, Andreas Berk
, Norbert Schmitz

Technische Universität Dresden
Charité – Universitätsmedizin Berlin
University of Münster
Heidelberg University
Institut Paoli Calmettes
Friedrich Schiller University Jena
Schwarzwald-Baar-Klinikum
Ulm University
University Hospital of South Lyon
Sungkyunkwan University
Seoul National University
Cardiff University
Goethe University Frankfurt
Boehringer Ingelheim GmbH
ClinTriCare GmbH & Co. KG

Research output: Contribution to journal › Comment/debate

Abstract

The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Original language	English
Pages (from-to)	283-284
Number of pages	2
Journal	Investigational New Drugs
Volume	39
Issue number	1
DOIs	https://doi.org/10.1007/s10637-020-00949-8
State	Published - Feb 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s10637-020-00949-8

Fingerprint

Dive into the research topics of 'Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)'. Together they form a unique fingerprint.

Cite this

Kroschinsky, F., Middeke, J. M., Janz, M., Lenz, G., Witzens-Harig, M., Bouabdallah, R., La Rosée, P., Viardot, A., Salles, G., Kim, S. J., Kim, T. M., Ottmann, O., Chromik, J., Quinson, A. M., von Wangenheim, U., Burkard, U., Berk, A., & Schmitz, N. (2021). Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3). Investigational New Drugs, 39(1), 283-284. https://doi.org/10.1007/s10637-020-00949-8

@article{7d8cd2881ad948f6ae9400d049733c46,

title = "Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)",

abstract = "The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.",

author = "Frank Kroschinsky and Middeke, \{Jan Moritz\} and Martin Janz and Georg Lenz and Mathias Witzens-Harig and Reda Bouabdallah and \{La Ros{\'e}e\}, Paul and Andreas Viardot and Gilles Salles and Kim, \{Seok Jin\} and Kim, \{Tae Min\} and Oliver Ottmann and Joerg Chromik and Quinson, \{Anne Marie\} and \{von Wangenheim\}, Ute and Ute Burkard and Andreas Berk and Norbert Schmitz",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2021",

month = feb,

doi = "10.1007/s10637-020-00949-8",

language = "English",

volume = "39",

pages = "283--284",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "1",

}

Kroschinsky, F, Middeke, JM, Janz, M, Lenz, G, Witzens-Harig, M, Bouabdallah, R, La Rosée, P, Viardot, A, Salles, G, Kim, SJ, Kim, TM, Ottmann, O, Chromik, J, Quinson, AM, von Wangenheim, U, Burkard, U, Berk, A & Schmitz, N 2021, 'Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)', Investigational New Drugs, vol. 39, no. 1, pp. 283-284. https://doi.org/10.1007/s10637-020-00949-8

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3). / Kroschinsky, Frank; Middeke, Jan Moritz; Janz, Martin et al.
In: Investigational New Drugs, Vol. 39, No. 1, 02.2021, p. 283-284.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)

AU - Kroschinsky, Frank

AU - Middeke, Jan Moritz

AU - Janz, Martin

AU - Lenz, Georg

AU - Witzens-Harig, Mathias

AU - Bouabdallah, Reda

AU - La Rosée, Paul

AU - Viardot, Andreas

AU - Salles, Gilles

AU - Kim, Seok Jin

AU - Kim, Tae Min

AU - Ottmann, Oliver

AU - Chromik, Joerg

AU - Quinson, Anne Marie

AU - von Wangenheim, Ute

AU - Burkard, Ute

AU - Berk, Andreas

AU - Schmitz, Norbert

PY - 2021/2

Y1 - 2021/2

N2 - The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

AB - The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

UR - https://www.scopus.com/pages/publications/85086784183

U2 - 10.1007/s10637-020-00949-8

DO - 10.1007/s10637-020-00949-8

M3 - Comment/debate

C2 - 32474843

AN - SCOPUS:85086784183

SN - 0167-6997

VL - 39

SP - 283

EP - 284

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1

ER -

Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R et al. Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3). Investigational New Drugs. 2021 Feb;39(1):283-284. doi: 10.1007/s10637-020-00949-8

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this